Abstract
Background Ischemia-related injury during the pre-implantation period impacts kidney graft outcome. Evaluating these lesions by a non-invasive approach before transplantation could help to understand the mechanisms of graft injury and identify potential biomarkers predictive of graft outcomes. This study aims to determine metabolomic content of graft perfusion fluids and its dependence on preservation time and to explore whether tubular transporters are possibly involved in the metabolomics variations observed.
Methods Kidneys were stored on hypothermic perfusion machines. We evaluated the metabolomic profiles of perfusion fluids (n=35) using Liquid Chromatography coupled with tandem Mass Spectrometry and studied the transcriptional expression of tubular transporters on pre-implantation biopsies (n=26). We used univariate and multivariate analyses to assess the impact of perfusion time on these parameters and their relationship with graft outcome.
Results Seventy-two metabolites were found in preservation fluids at the end of perfusion, of which 40% were already present in the native conservation solution. We observed an increase of 23 metabolites with longer perfusion time and a decrease for 8. The predictive model for time-dependent variation of metabolomics content showed good performance (R2= 76%, Q2= 54%, accuracy= 41%, permutations test significant). Perfusion time had no effect on the mRNA expression of transporters. We found no correlation between metabolomics and transporters expression. Neither the metabolomics profile nor the transporters expression were predictive of graft outcome.
Conclusion Our results open the way for further studies, focusing on both intra- and extra-tissue metabolome, to investigate whether transporter alterations can explain the variations observed in pre-implantation period.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03024229
Funding Statement
Funding for this research was provided by Organ Recovery System
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was obtained from Tours university hospital (IRB ID/CPP : 16-10-40) Clinical trial was registered with access number: NCT03024229
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Clinical Trial Notation: Metabolomics in assessing the quality of kidney transplants retained on a Lifeport® Perfusion Machine (RENALIFE), ClinicalTrials.gov NCT03024229
AUTHORSHIP PAGE Q.F.: Participated in research design, data collection, analysis and interpretation, and the writing of the article. H.A.: Participated in research design, data collection, analysis and interpretation, and the writing of the article. F.L.S.: Participated in data analysis, and the writing of the article. L.F.: Participated in data analysis, and article review. E.M.S.: Participated in data collection and article review. L.N.: Participated in data analysis and article review. H.A(2): Participated in data analysis, and article review. J.C.V.: Participated in research design and data collection. N.B.: Participated in research design and data collection. F.B.: Participated in research design and data collection. P.M.: Participated in research design, data analysis and interpretation, and article review. C.B.L.G.: Participated in research design, data collection, analysis and interpretation, and the writing of the article.
Disclosure: The authors have no conflicts of interest to declare.
Funding: funding for this research was provided by Organ Recovery System.
author affiliations updated
Data Availability
Data are available upon request
ABBREVIATIONS PAGE
- ABC
- ATP-binding cassette
- CIM
- clustered image maps
- DGF
- delayed graft function
- ECD
- expanded criteria donors
- FC
- fold change
- FDR
- false discovery rate
- HMP
- hypothermic machine perfusion
- IGF
- immediate graft function
- IRI
- ischemia-reperfusion injury
- LC-MS/MS
- liquid chromatography/tandem mass spectrometry
- NMR
- nuclear magnetic resonance
- PCA
- principal component analysis
- PLS
- partial least squares
- PLS-DA
- partial least squares discriminant analysis
- RF
- random forest
- RIN
- RNA integrity number
- SCS
- static cold storage
- SLC
- solute carrier